Recent Updates
Recently added Catalysts

Genelux Corporation

GNLXFDA catalysts, PDUFA dates & pipeline intelligence
$2
▲ +0.08 · +4.17%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full GNLX financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $1.7752W HIGH $5.89
Volume
251.78 K
Value Traded
495.22 K
Short % Float
11.65%
Days to Cover
8.3
+6.38%Week
-18.37%1 Month
-25.37%3 Month
-31.74%6 Month
-51.33%5 Year
-51.33%All Time

Cash Data

Unlock GNLX cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
90.49 M
EPS (TTM)
-0.84
P/E Ratio
-
Ent. Value
80.05 M
Total Shares
45.25 M
Float Shares
38.89 M
Insiders
14.05%
Institutions
31.73%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 3 topline data readout
Olvi-Vec
Platinum-resistant/refractory ovarian cancer (including fallopian tube and primary peritoneal cancers)
Fast Track
Phase 3Oncolytic VirusesOncology
Unlock every GNLX catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

GNLX Catalyst Timeline

Dated clinical, regulatory and corporate events for Genelux Corporation

Catalyst Timeline

Dated clinical, regulatory & corporate events for Genelux Corporation

126Total events
5Upcoming
22Tier-1 (high impact)
2012 to 2027Coverage

Upcoming catalysts 2

T2Dose Finding Update
Subscribe to view catalyst details
Olvi-Vec
T1Topline Readout
Subscribe to view catalyst details
Olvi-Vec

Event history 50

●Quarterly UpdateCorporate
Genelux reports third quarter 2026 financial results
▲PublicationOlvi-VecPresentation
Publication of case report in Frontiers in Oncology of platinum-relapsed SCLC patient treated with Olvi-Vec-primed immunochemotherapy
Platinum-relapsed Small Cell Lung Cancersource ↗
▲PublicationOlvi-VecPresentation
Case report of deep durable response with systemic Olvi-Vec in SCLC published
platinum-relapsed small cell lung cancersource ↗
●Quarterly UpdateCorporate
Second quarter 2026 financial results reported
▲PublicationOlvi-VecPresentation
Publication of translational analysis from VIRO-15 trial in Gynecologic Oncology Reports
platinum-resistant/refractory ovarian cancersource ↗
▲PublicationOlvi-VecPresentation
Publication of translational analyses from VIRO-15 trial in Gynecologic Oncology Reports
ovarian cancersource ↗
●Quarterly UpdateCorporate
First quarter 2026 financial results reported
◆Topline ReadoutOlvi-VecClinical Data
Topline data from Phase 3 OnPrime/GOG-3076 trial expected in 2H26
platinum-resistant/refractory ovarian cancersource ↗
●Quarterly UpdateCorporate
Fourth quarter and full year 2025 financial results
◆Oral PresentationPresentation
Participation in two upcoming conferences with live webcasts
Unlock the full GNLX catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How GNLX actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-01-05Olvi-Vec Phase 2 interim results Phase 2
Unlock 1 more GNLX historical catalyst
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 44%
Micro Cap
(rank 320 of 725)
Percentile Rank
Showing 3 of 7 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Olvimulogene nanivacirepvec Oncolytic VirusesNCT05281471Platinum-resistant Ovarian CancerPhase 3 RECRUITING 186Dec 1, 2027
Olvimulogene nanivacirepvec Oncolytic VirusesNCT06463665Advanced Non-squamous Non-small-cell Lung CancerPhase 2 RECRUITING 142Jul 1, 2029
Olvimulogene nanivacirepvec Oncolytic VirusesCompletedNCT02759588Ovarian CancerPhase 1/2 COMPLETED 46Dec 31, 2022
Unlock the GNLX pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every GNLX program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Olvi-Vec
Fast Track
platinum-relapsed small cell lung cancerPhase 1b2026-09-09progression free survival: 16.7 months; tumor size reduction: 84.6%; first line pfs: 14.3 months; first line dor: 13.0 months; tumor reduction after rechallenge: -78.9%; first line tumor reduction: -67.8%; absolute reduction: 22.0 mm; first line absolute reduction: 11.6 mmRead MoreGenelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed ImmunochemotherapyRead More
Scroll for more · summaries link to the source press release
Unlock every GNLX trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock GNLX insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Yu YongOfficer (Chief Scientific Officer)Sell -668 258,020 held$2.01 11/03/2026
Unlock the full GNLX insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
AFFINITY ASSET ADVISORS, LLC 0 % 237.00 K 100.00 K
Unlock every fund holding GNLX
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in GNLX
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see GNLX ownership
Insider and institutional ownership, quarter by quarter.

GNLX Short Interest

Shares sold short, counted twice a month.

11.65%
Short % of Float
of tradable shares sold short
4.5M
Shares Sold Short
-2.4% vs prior count
8.3 High
Days to Cover
trading days of normal volume to buy every short share back
544.6K
Avg Daily Volume
the average used for days to cover
Unlock GNLX short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock GNLX option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live GNLX option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock GNLX options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How GNLX ranks across every disease it competes in

Competitive Position is a premium feature
See how GNLX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

GNLX News

GNLX
Nov 16, 2026
GNLXGeneral
▲ +4.2%today

Genelux Corporation Reports Third Quarter Financial Results and Provides Business Updates

Genelux Corporation reported its Q3 2026 financial results, highlighting progress in its clinical programs. The company anticipates topline data from its Phase 3 OnPrime trial in ovarian cancer by the second half of 2026. Olvi-Vec's systemic development in lung cancer shows promising results, with ongoing trials expected to refine dosing regimens. The company has $15.5 million in cash to support operations into early 2027.

Read more →
GNLX
Sep 9, 2026
GNLXPhases

Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy

Genelux Corporation announced a significant case report detailing a platinum-relapsed small cell lung cancer patient who achieved 16.7 months of progression-free survival following treatment with Olvi-Vec and platinum chemotherapy. The patient also experienced an 84.6% reduction in tumor size, suggesting that Olvi-Vec may enhance the effectiveness of chemotherapy. Ongoing trials are evaluating the systemic administration of Olvi-Vec in lung cancer.

Read more →
GNLX
Aug 13, 2026
GNLXPhases

Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates

Genelux Corporation reported its second quarter financial results, highlighting ongoing advancements in its clinical programs, particularly for Olvi-Vec in ovarian and lung cancers. The company anticipates topline data from its Phase 3 OnPrime/GOG-3076 trial in the second half of 2026, while also addressing operational capabilities for future commercialization. Financially, Genelux has $18.7 million in cash, expected to sustain operations into early 2027.

Read more →
GNLX
Jun 30, 2026
GNLXPhases

Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer

Genelux Corporation announced the publication of findings from its Phase 1b/2 VIRO-15 trial, highlighting the potential of Olvi-Vec to enhance chemotherapy sensitivity in platinum-resistant ovarian cancer. The study demonstrates that Olvi-Vec can modulate the tumor microenvironment and activate immune responses, supporting the ongoing Phase 3 OnPrime/GOG-3076 trial. The findings suggest a promising avenue for improving treatment outcomes in patients with limited options.

Read more →
GNLX
May 7, 2026
GNLXPhases

Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates

Genelux Corporation reported its first quarter financial results, revealing a cash position of $26.3 million expected to support operations into Q1 2027. The company is progressing with its Phase 3 OnPrime/GOG-3076 trial for Olvi-Vec in platinum-resistant ovarian cancer, with topline data anticipated in the second half of 2026. Additionally, Genelux is pursuing systemic lung cancer programs, with updates expected throughout 2026. However, the financial report noted a net loss of $8.9 million, indicating ongoing challenges as operational costs rise.

Read more →
GNLX
Mar 19, 2026
GNLXPhases

Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Genelux Corporation announced its fourth quarter and full year 2025 financial results while providing updates on clinical trials and operations. The company is poised for significant developments in 2026, with topline data from the Phase 3 OnPrime trial for Olvi-Vec expected in the second half of the year. Interim data has shown promise in lung cancer trials, and the recent appointment of Dr. Jason Litten as Chief Medical Officer aims to bolster the clinical development strategy. The company's financial position was strengthened by a successful stock offering, securing $18.5 million to fund ongoing operations.

Read more →
GNLX
Feb 18, 2026
GNLXConferences/Events

Genelux Corporation to Participate in Upcoming Conferences

Genelux Corporation will present at two upcoming healthcare conferences. President Thomas Zindrick and CFO Matt Pulisic will attend the TD Cowen 46th Annual Health Care Conference on March 2. The full leadership team will join a virtual fireside chat at the Oppenheimer Healthcare Life Sciences Conference on February 25. These events allow investors to hear directly from company executives regarding their clinical-stage immuno-oncology pipeline.

Read more →
GNLX
Jan 13, 2026
GNLXConferences/Events

Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners

Genelux Corporation announced a virtual fireside chat featuring its CEO, CFO, and CMO on January 19, 2026. The chat will be hosted by Titan Partners and will discuss the company's developments in immuno-oncology. Genelux is focused on oncolytic immunotherapies, with ongoing clinical trials for its lead product, Olvi-Vec, in various cancer types.

Read more →
GNLX
Jan 9, 2026
GNLXGeneral

Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock

Genelux Corporation has announced the pricing of an underwritten public offering, aiming to raise approximately $20 million by selling 6,666,667 shares at $3.00 each. The proceeds will be allocated for general corporate purposes, including R&D and clinical trials. The offering is expected to close on January 9, 2026, pending customary conditions.

Read more →
GNLX
Jan 7, 2026
GNLXGeneral

Corporation Announces Proposed Public Offering of Common Stock

Genelux Corporation has announced its proposed underwritten public offering of common stock, which includes a 30-day option for underwriters to purchase additional shares. This offering is part of its strategy to raise funds as the company advances its clinical-stage immuno-oncology programs. However, the offering is contingent on market conditions and customary closing requirements, leaving its success uncertain. The company specializes in developing oncolytic immunotherapies for challenging solid tumor types, enhancing its capital resources may support these efforts.

Read more →
GNLX
Jan 5, 2026
GNLXPhases
▼ -23.5%on this news· ran to -40% by day 3shared move

Genelux Corporation Reports Encouraging Interim Data of Systemic Administration of Olvi-Vec in Ongoing Lung Cancer Trials

Genelux Corporation has reported encouraging interim data from its ongoing trials of Olvi-Vec for lung cancer treatment. In the Phase 1b/2 trial for small cell lung cancer (SCLC), two of three patients in the highest dose cohort showed significant tumor shrinkage. The Phase 2 trial for non-small cell lung cancer (NSCLC) also indicated anti-tumor activity. Further data is expected throughout 2026.

Read more →
GNLX
Jan 2, 2026
GNLXGeneral

Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer

Genelux Corporation has appointed Dr. Jason Litten as Chief Medical Officer, effective January 2, 2026. Dr. Litten will oversee clinical development and medical strategy for the company's immunotherapy, Olvi-Vec. His extensive experience in oncology and leadership in drug development is expected to enhance Genelux's clinical efforts as they approach pivotal trials in ovarian and lung cancer.

Read more →
GNLX
Nov 26, 2025
GNLXConferences/Events
▲ +5.7%on this news

Genelux Corporation to Participate in a Fireside Chat at Piper Sandler 37th Annual Healthcare Conference

Genelux Corporation will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025. CEO Thomas Zindrick and CFO Matt Pulisic will represent the company during the event. Genelux is advancing its oncolytic immunotherapy, Olvi-Vec, through several clinical trials targeting difficult-to-treat cancers.

Read more →
GNLX
Nov 5, 2025
GNLXGeneral
▼ -32.4%on this news

Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates

Genelux Corporation reported its third quarter 2025 financial results, highlighting progress in its lung cancer and ovarian cancer programs. The company anticipates interim data from its lung cancer studies in Q4 2025 and topline results from its Phase 3 ovarian cancer trial in the second half of 2026. Despite an increase in net loss and R&D expenses, Genelux remains optimistic about its pipeline and market opportunities.

Read more →
GNLX
Sep 2, 2025
GNLXConferences/Events

Genelux Corporation to Participate in a Fireside Chat at H.C. Wainwright Global Investment Conference

Genelux Corporation will participate in a fireside chat at the H.C. Wainwright Global Investment Conference on September 9, 2025. The session will be moderated by Emily Bodnar and will include one-on-one meetings with institutional investors. Genelux is focused on developing oncolytic immunotherapies, with its lead product, Olvi-Vec, being evaluated in multiple clinical trials.

Read more →
GNLX
Aug 7, 2025
GNLXGeneral
▼ -7%on this news

Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates

Genelux Corporation announced its financial results for the second quarter of 2025, reporting a net loss of $7.5 million. The company is working on advancing its candidate, Olvi-Vec, with key clinical readouts expected in the near future, especially for platinum-resistant ovarian cancer. Recent collaborations with the FDA could facilitate a traditional approval pathway for their trials. The appointment of Eric Groen as a new executive is anticipated to strengthen Genelux's leadership as it navigates upcoming developments.

Read more →
GNLX
Jul 7, 2025
GNLXGeneral

Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development

Genelux Corporation has appointed Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer, and Head of Business Development, effective July 1, 2025. Groen brings over two decades of experience in the life sciences industry, having previously served as General Counsel at Rani Therapeutics and spent 20 years at Amgen. His expertise is expected to enhance Genelux's strategic growth and development of its lead product, Olvi-Vec.

Read more →
GNLX
May 6, 2025
GNLXGeneral
▼ -7.2%on this news· ran to +18% by day 3

Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates

Genelux Corporation announced its financial results for the first quarter of 2025, reporting a net loss of $7.5 million while highlighting progress in its clinical programs. The company received positive regulatory feedback from the FDA regarding its Olvi-Vec treatment for platinum-resistant/refractory ovarian cancer and is seeing increased patient enrollment in trials for lung cancer. Genelux also strengthened its finances through a recent equity raise, allowing further advancement of its strategic initiatives amid ongoing clinical trials.

Read more →
GNLX
May 1, 2025
GNLXConferences/Events
▲ +8.5%on this newsshared move

Genelux Corporation to Participate in a Fireside Chat at the Citizens Life Sciences Conference

Genelux Corporation will participate in a fireside chat at the Citizens Life Sciences Conference on May 8, 2025. CEO Thomas Zindrick and CFO Matt Pulisic will discuss the company's clinical-stage programs, including trials for their oncolytic immunotherapy, Olvi-Vec. The event will be webcasted, and one-on-one meetings will be available for institutional investors.

Read more →
GNLX
Mar 28, 2025
GNLXFDA Updates

Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Genelux Corporation announced its fourth quarter and full year 2024 financial results, highlighting significant advancements in its clinical development. The company has reached alignment with the FDA regarding approval pathways for its candidate Olvi-Vec in treating platinum-resistant ovarian cancer, while also reporting promising preliminary data from ongoing trials in small-cell lung cancer. Additionally, Genelux closed a $10.5 million underwritten offering that enhances its financial position. Despite these positive developments, the company reported a net loss of $29.9 million for the year.

Read more →

About Genelux Corporation

Westlake Village, CA 26 employees genelux.com
Headquarters2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361
BIOPHARMAWATCH ELITE
Trade the next GNLX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime